查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1594472

神经生物标记物市场：按类型、应用和最终用户划分 - 2025-2030 年全球预测

Neurological Biomarkers Market by Type (Genomic, Imaging, Metabolomic), Application (Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis), End-user - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

神经生物标记市场2023年估值为89.8亿美元，预计到2024年将达到102.4亿美元，复合年增长率为14.05%，到2030年将达到225.6亿美元。

神经生物标记是与中枢神经系统相关的生物状况的可测量指标，已成为神经系统疾病诊断和治疗的关键工具。随着生物标记的定义不断扩大，它已包括遗传标记、蛋白质和表明大脑功能和结构变化的成像观察。阿兹海默症、帕金森氏症和多发性硬化症等神经系统疾病的盛行率不断上升证明了这一需求，早期准确的诊断可显着改善患者的预后。这些生物标记可应用于药物开发、监测疾病进展和客製化治疗策略，最终用途包括研究机构、医疗机构和製药公司。市场成长的关键驱动力是神经系统疾病盛行率的上升、生物标记技术的进步、研究经费的增加。主要商机在于非侵入性生物标誌物的开发及其与人工智慧的集成，以提高诊断准确性。创新是神经系统疾病液态切片以及基因组学和蛋白​​质组学融合等领域的关键。然而，市场开拓受到监管复杂性、研发高成本以及新型生物标记候选物临床检验限制等挑战的阻碍。此外，对生物标记研究的伦理影响和病人隐私的担忧构成了重大障碍。为了克服这些问题，相关人员应专注于简化监管途径、促进公私合作以及倡导道德准则和病患资料保护。神经生物标记市场的本质是动态的、多学科的，需要神经科学家、生物技术专家和医学专业人士采取协同方法。为了实现可持续的业务成长，公司需要投资强有力的研发，探索与学术研究机构的合作机会，并瞄准医疗基础设施正在改善的新兴市场。采用这些策略可以加强竞争并扩大神经生物标记对全球医疗保健的影响。

主要市场统计
基准年[2023] 89.8亿美元
预测年份 [2024] 102.4亿美元
预测年份 [2030] 225.6亿美元
复合年增长率（%） 14.05%

市场动态：揭示快速发展的神经生物标记物市场的关键市场洞察

供需的动态交互作用正在改变神经生物标记市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 神经系统疾病盛行率增加
    • 对具有成本效益的非侵入性诊断系统的需求
    • 人们越来越偏好早期诊断和预防性治疗
  • 市场限制因素
    • 严格的政府核准规定
  • 市场机会
    • 越来越关註生物标誌物进步的研究和开发
    • 单细胞生物感测器的兴起
    • 开发中国家低成本临床试验的增加
  • 市场问题
    • 伦理问题和神经系统疾病的接受问题

波特的五力：驾驭神经生物标记市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架描述了评估公司竞争和探索策略机会的清晰方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解神经生物标记物市场的外部影响

外部宏观环境因素在塑造神经生物标记市场的绩效动态发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析：了解神经生物标记市场的竞争格局

神经生物标记物市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、细分和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵：神经生物标记物市场供应商的绩效评估

FPNV 定位矩阵是评估神经生物标记市场供应商的重要工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议：绘製神经生物标记物市场的成功之路

神经生物标记物市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

该报告对涵盖关键焦点细分市场的市场进行了全面分析。

1.市场渗透率：对当前市场环境的详细审查，主要企业的广泛资料，评估他们在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有细分市场的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5.产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策。

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品和地区提供最佳投资机会？

3.塑造市场的关键技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 神经系统疾病增加
      • 对具有成本效益和非侵入性诊断系统的需求
      • 对早期诊断和预防性治疗的兴趣增加
    • 抑制因素
      • 有关核准的严格政府法规
    • 机会
      • 扩大研发重点以促进生物标誌物的发展
      • 新型单细胞生物感测器
      • 新兴国家低成本临床试验的增加
    • 任务
      • 伦理问题和神经系统疾病的接受问题
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 经济
    • 社会
    • 科技
    • 法律
    • 环境

第六章神经生物标记市场：依类型

  • 介绍
  • 基因组
  • 影像
  • 代谢体学
  • 蛋白质体

第七章神经生物标记市场：依应用分类

  • 介绍
  • 阿兹海默症
  • 泛自闭症障碍
  • 多发性硬化症
  • 帕金森氏症

第 8 章 神经生物标记市场：依最终用户分类

  • 介绍
  • 医院实验室
  • 独立临床诊断中心
  • 研究所

第9章美洲神经生物标记市场

  • 介绍
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第10章亚太神经生物标记市场

  • 介绍
  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的神经生物标记市场

  • 介绍
  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Acumen Pharmaceuticals, Inc
  • Alseres Pharmaceuticals, Inc.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Imagilys
  • inviCRO, LLC by Konica Minolta Business Solutions USA, Inc.
  • IXICO PLC
  • Merck KGaA
  • Proteome Sciences PLC
  • QIAGEN GmbH
  • Quanterix Corporation
  • Quest Diagnostics Incorporated
  • Rules-Based Medicine by Q2 Solutions
  • Thermo Fisher Scientific Inc.
Product Code: MRR-AD36CD897EE7

The Neurological Biomarkers Market was valued at USD 8.98 billion in 2023, expected to reach USD 10.24 billion in 2024, and is projected to grow at a CAGR of 14.05%, to USD 22.56 billion by 2030.

Neurological biomarkers, measurable indicators of a biological condition related to the central nervous system, have emerged as crucial tools in diagnosing and managing neurological diseases. As their definition broadens, these biomarkers include genetic markers, proteins, and imaging findings that signal changes in brain function or structure. Their necessity is underscored by the increasing prevalence of neurological disorders such as Alzheimer's, Parkinson's, and multiple sclerosis, where early and accurate diagnosis can significantly improve patient outcomes. These biomarkers find application in drug development, monitoring disease progression, and customizing therapeutic strategies, with end-use spanning research institutions, healthcare facilities, and pharmaceutical companies. Market growth is primarily driven by the rising incidence of neurological conditions, advancements in biomarker technology, and increased research funding. Key opportunities lie in the development of non-invasive biomarkers and integration with artificial intelligence to enhance diagnostic precision. Innovation is critical in areas like liquid biopsy for neurological conditions and the convergence of genomics and proteomics. However, market growth is hindered by challenges such as regulatory complexities, high costs of research and development, and limited clinical validation of new biomarker candidates. Additionally, the ethical implications of biomarker research and patient privacy concerns pose significant barriers. To overcome these, stakeholders should focus on streamlining regulatory pathways, fostering public-private collaborations, and advocating for ethical guidelines and patient data protection. The nature of the neurological biomarkers market is dynamic and interdisciplinary, demanding a synergistic approach among neuroscientists, biotechnologists, and healthcare professionals. For sustained business growth, companies should invest in robust R&D, explore collaboration opportunities with academic and research institutions, and target emerging markets where healthcare infrastructure is improving. Embracing these strategies will enhance competitiveness and expand the impact of neurological biomarkers on global healthcare.

KEY MARKET STATISTICS
Base Year [2023] USD 8.98 billion
Estimated Year [2024] USD 10.24 billion
Forecast Year [2030] USD 22.56 billion
CAGR (%) 14.05%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neurological Biomarkers Market

The Neurological Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing prevalence of neurological disorders
    • Demand for cost-effective and non-invasive diagnostic system
    • Increasing preferences on early diagnosis & preventive treatment
  • Market Restraints
    • Stringent government regulations for approvals
  • Market Opportunities
    • Growing R&D focus for advancements in biomarkers
    • Emerging single-cell biosensors
    • Growth of low-cost clinical trials in developing countries
  • Market Challenges
    • Ethical problems and acceptance issues of neurological disorders

Porter's Five Forces: A Strategic Tool for Navigating the Neurological Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neurological Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neurological Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neurological Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neurological Biomarkers Market

A detailed market share analysis in the Neurological Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neurological Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neurological Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neurological Biomarkers Market

A strategic analysis of the Neurological Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neurological Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Acumen Pharmaceuticals, Inc, Alseres Pharmaceuticals, Inc., Bio-Rad Laboratories, Inc., bioMerieux SA, Imagilys, inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc., IXICO PLC, Merck KGaA, Proteome Sciences PLC, QIAGEN GmbH, Quanterix Corporation, Quest Diagnostics Incorporated, Rules-Based Medicine by Q2 Solutions, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Neurological Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Genomic, Imaging, Metabolomic, and Proteomic.
  • Based on Application, market is studied across Alzheimer's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Parkinson's Disease.
  • Based on End-user, market is studied across Hospital Laboratories, Independent Clinical Diagnostic Centers, and Research Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing prevalence of neurological disorders
      • 5.1.1.2. Demand for cost-effective and non-invasive diagnostic system
      • 5.1.1.3. Increasing preferences on early diagnosis & preventive treatment
    • 5.1.2. Restraints
      • 5.1.2.1. Stringent government regulations for approvals
    • 5.1.3. Opportunities
      • 5.1.3.1. Growing R&D focus for advancements in biomarkers
      • 5.1.3.2. Emerging single-cell biosensors
      • 5.1.3.3. Growth of low-cost clinical trials in developing countries
    • 5.1.4. Challenges
      • 5.1.4.1. Ethical problems and acceptance issues of neurological disorders
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Neurological Biomarkers Market, by Type

  • 6.1. Introduction
  • 6.2. Genomic
  • 6.3. Imaging
  • 6.4. Metabolomic
  • 6.5. Proteomic

7. Neurological Biomarkers Market, by Application

  • 7.1. Introduction
  • 7.2. Alzheimer's Disease
  • 7.3. Autism Spectrum Disorders
  • 7.4. Multiple Sclerosis
  • 7.5. Parkinson's Disease

8. Neurological Biomarkers Market, by End-user

  • 8.1. Introduction
  • 8.2. Hospital Laboratories
  • 8.3. Independent Clinical Diagnostic Centers
  • 8.4. Research Organizations

9. Americas Neurological Biomarkers Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Neurological Biomarkers Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Neurological Biomarkers Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Acumen Pharmaceuticals, Inc
  • 3. Alseres Pharmaceuticals, Inc.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Imagilys
  • 7. inviCRO, LLC by Konica Minolta Business Solutions U.S.A., Inc.
  • 8. IXICO PLC
  • 9. Merck KGaA
  • 10. Proteome Sciences PLC
  • 11. QIAGEN GmbH
  • 12. Quanterix Corporation
  • 13. Quest Diagnostics Incorporated
  • 14. Rules-Based Medicine by Q2 Solutions
  • 15. Thermo Fisher Scientific Inc.

LIST OF FIGURES

  • FIGURE 1. NEUROLOGICAL BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. NEUROLOGICAL BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. NEUROLOGICAL BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. NEUROLOGICAL BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY GENOMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY IMAGING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY METABOLOMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PROTEOMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY ALZHEIMER'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY AUTISM SPECTRUM DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY PARKINSON'S DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY HOSPITAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY INDEPENDENT CLINICAL DIAGNOSTIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM NEUROLOGICAL BIOMARKERS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 148. NEUROLOGICAL BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. NEUROLOGICAL BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023